The Frog Gut Bacterium That Eliminated Tumors in Every Treated Mouse

There is a moment in cancer research when the data stops looking like data and starts looking like something else entirely.

A tumor disappears.

A survival curve stops heading downward.

A treatment works after a single dose, and the tumor does not return during the observation period.

That is what researchers at the Japan Advanced Institute of Science and Technology (JAIST) reported in a study published in Gut Microbes in December 2025.

The researchers identified a bacterium called Ewingella americana in the intestines of Japanese tree frogs (Dryophytes japonicus). In experiments using a mouse model of colorectal cancer, a single intravenous administration of the bacterium produced complete tumor regression in all treated mice.

The finding is striking, but it is also important to understand exactly what the study demonstrates. This was a preclinical study in mice, not a clinical trial in humans.

Still, the biology behind the result is fascinating.

A Bacterium From a Frog's Gut

The study, titled "Discovery and characterization of antitumor gut microbiota from amphibians and reptiles: Ewingella americana as a novel therapeutic agent with dual cytotoxic and immunomodulatory properties," was authored by Seigo Iwata, Nagi Yamasita, Kensuke Asukabe, Matomo Sakari and Eijiro Miyako. It was published online on December 10, 2025, with the DOI 10.1080/19490976.2025.2599562.

The researchers were looking for bacteria with potential anticancer properties in an unusual place: the intestinal microbiota of amphibians and reptiles.

They examined bacterial isolates obtained from Japanese tree frogs, Japanese fire-bellied newts (Cynops pyrrhogaster), and Japanese grass lizards (Takydromus tachydromoides).

From this work, nine bacterial strains were selected for further investigation because they demonstrated antitumor activity.

One stood out.

Ewingella americana demonstrated particularly strong cytotoxic activity and an ability to selectively target tumors. The researchers described the bacterium as a facultative anaerobe, meaning it can grow in both oxygen-rich and oxygen-poor environments. This characteristic appears to be important because solid tumors often contain regions with very low oxygen levels.

One Injection, Complete Tumor Regression

The most dramatic experiment involved mice bearing Colon-26 tumors, a commonly used immunocompetent mouse model for studying colorectal cancer.

When the tumors reached approximately 200 mm³, the researchers administered E. americana intravenously through the tail vein.

The treatment was given as a single injection.

According to the study, the optimal dose was 1 × 10⁹ colony-forming units (CFU). At this dose, the researchers observed complete tumor regression in the treated mice. Tumor growth was monitored for up to 40 days following treatment.

The comparison with conventional therapies was particularly interesting.

The researchers compared E. americana with doxorubicin and an anti-PD-L1 immune checkpoint inhibitor.

The bacterial treatment involved a single administration, while the comparison groups received multiple treatments. The researchers reported significantly stronger tumor regression with E. americana than with the conventional treatment groups in their experimental model.

But the result was not simply about killing cancer cells directly.

The researchers found evidence for a second mechanism.

The Tumor May Be Its Own Weakness

One of the defining characteristics of many solid tumors is their abnormal internal environment.

As tumors grow rapidly, their blood supply may fail to keep pace with their demands. This can produce regions of hypoxia, where oxygen concentrations are substantially lower than in normal tissue.

Tumors can also develop mechanisms that suppress immune activity, helping malignant cells evade destruction by the body's immune system.

For most therapies, these features are obstacles.

For certain bacteria, they can potentially become opportunities.

The researchers found that E. americana was capable of preferentially proliferating within the tumor environment. Its ability to survive under low-oxygen conditions appears to contribute to its tumor-targeting behaviour.

This creates an intriguing therapeutic possibility.

Instead of designing a conventional drug that has to reach every part of a tumor, researchers could potentially use a microorganism capable of naturally accumulating in one of the tumor's most difficult environments.

The bacterium effectively exploits a feature that helps tumors survive.

The Bacterium Does More Than Attack the Tumor

The researchers found that the antitumor effect of E. americana was not limited to direct bacterial killing.

Their experiments suggested a dual mechanism involving both direct cytotoxicity and activation of the host immune response.

The study reported increased involvement of several immune-cell populations following bacterial treatment, including:

• CD8+ T cells


• CD4+ T cells


• B cells


• Neutrophils

The researchers therefore proposed that E. americana can act both as a direct cytotoxic agent and as an immunomodulatory agent, helping stimulate an immune response against the tumor.

This distinction is important.

The bacterium is not simply functioning as a microscopic poison.

It appears to create a biological chain reaction in which bacterial activity contributes to tumor destruction while simultaneously encouraging the immune system to participate.

What Happens After the Tumor Disappears?

Perhaps the most interesting question is what happens after the initial tumor has been eliminated.

Cancer treatment is not only about destroying an existing tumor. Researchers also want to know whether the immune system can develop lasting protection against the disease.

In the study, mice that had experienced complete tumor regression were subsequently subjected to tumor rechallenge experiments.

The researchers reported that these previously treated mice were able to resist the subsequent tumor challenge, providing evidence consistent with the development of antitumor immune memory.

That finding supports the idea that the treatment may do more than destroy the original tumor. It may also help the immune system recognise tumor-associated targets and respond more effectively when they appear again.

The Bacterium Also Produced Direct Cytotoxic Effects

The researchers investigated the bacterium's ability to kill cancer cells directly using three-dimensional Colon-26 tumor spheroids.

These models are useful because they more closely reproduce some structural characteristics of solid tumors than conventional two-dimensional cell cultures.

When the spheroids were exposed to E. americana, the researchers observed concentration-dependent and time-dependent disruption and cancer-cell death.

At the highest concentration tested, the spheroids were largely destroyed within approximately 24 hours.

The study also identified bacterial factors including hemolysin and exotoxin as potential contributors to the bacterium's cytotoxic activity.

This provides another piece of the puzzle.

The bacterium appears capable of directly damaging tumor cells while also triggering an immune response against the tumor.

But Is It Safe?

This is where the results become more complicated.

Introducing a live bacterium into the bloodstream is not inherently safe. Any potential bacterial cancer therapy must demonstrate that the organism can preferentially target tumors without causing dangerous systemic infection or toxicity.

The researchers therefore conducted safety experiments in their mouse models.

At the therapeutically effective dose, they reported minimal pathogenicity and no significant adverse effects in the measured parameters. They also observed that the bacterium was cleared from healthy organs while persisting preferentially in tumor tissue.

However, there is an important detail that should not be overlooked.

The researchers found that doses above 1 × 10⁹ CFU resulted in acute mortality in the mice. This established the 1 × 10⁹ CFU dose as the maximum tolerated dose for the subsequent experiments.

That finding is a useful reminder that the treatment is not simply a case of "more bacteria means more cancer killing."

There is a therapeutic window that must be carefully controlled.

Why This Is Different From Conventional Cancer Therapy

Modern cancer treatment contains several broad strategies.

Chemotherapy uses cytotoxic drugs to exploit differences between cancer cells and normal cells, particularly their tendency to divide rapidly.

Immunotherapy can remove inhibitory signals that prevent immune cells from attacking tumors.

Targeted therapies attempt to interfere with specific molecular pathways that cancer cells depend upon.

The approach described in this study is different.

Instead of relying entirely on a synthetic molecule, researchers are investigating whether a living microorganism can act as a tumor-targeting therapeutic agent.

The bacterium brings several biological properties with it.

It can survive under low-oxygen conditions.

It can accumulate within the tumor environment.

It can directly damage cancer cells.

It can interact with the immune system.

And, at least in this mouse model, the resulting immune response can persist after the original tumor has disappeared.

That combination is what makes the research particularly interesting.

Evolution May Have Already Solved Part of the Problem

There is something almost counterintuitive about the discovery.

Ewingella americana did not evolve to treat cancer.

The Japanese tree frog did not evolve an anticancer therapy for humans.

The bacterium evolved to survive in its own biological environment.

Researchers are now investigating whether some of those evolutionary adaptations can be repurposed for medicine.

Tumors create unusual environments, including regions of low oxygen, altered metabolism and immune suppression. Certain microorganisms are naturally adapted to environments that conventional medicines may find difficult to reach.

The researchers' work suggests that these organisms could represent an underexplored source of potential cancer therapeutics.

Instead of designing every therapeutic property from scratch, scientists could search nature for organisms that already possess useful biological capabilities.

From Mouse Experiment to Human Treatment

This is where the excitement needs to be balanced with caution.

The study does not show that Ewingella americana can cure cancer in humans.

It does not establish that the bacterium is safe for intravenous administration in humans.

It does not demonstrate effectiveness against human colorectal cancer.

And it does not establish that the same results would occur across different cancer types.

The experiments were conducted primarily using the Colon-26 mouse tumor model, alongside laboratory experiments examining bacterial cytotoxicity and immune responses.

The distance between an impressive animal experiment and an approved human treatment is enormous.

Before a therapy like this could become a clinical treatment, researchers would need to establish its safety, pharmacology, mechanism of action and reproducibility through increasingly rigorous studies, followed by appropriately designed human clinical trials.

There is also the question of how the human immune system would respond to the bacterium.

A microorganism that behaves safely within a controlled mouse experiment may behave very differently in humans.

A New Way to Think About Cancer Therapy

Even with those limitations, the research points toward an intriguing direction.

Cancer researchers have spent decades developing molecules designed to attack tumors.

What if some future therapies are not molecules at all?

What if they are living organisms engineered or selected to seek out the biological weaknesses of tumors?

That concept is already being explored in bacterial cancer therapy research, but the E. americana findings add another unusual candidate to the field.

The researchers' work suggests that naturally occurring bacteria from amphibian and reptile microbiomes may contain previously unexplored properties that could be relevant to cancer treatment.

The broader lesson may be even more interesting.

Nature has spent millions of years producing organisms capable of surviving in extraordinarily hostile environments.

Some of those environments happen to resemble the conditions found inside tumors.

The challenge for researchers is to determine whether those biological adaptations can be harnessed safely.

The Frog Did Not Cure Cancer

Not yet, at least.

What researchers have discovered is more subtle and perhaps more interesting.

A bacterium isolated from the gut of a Japanese tree frog demonstrated remarkable antitumor activity in a mouse model of colorectal cancer.

A single intravenous treatment produced complete tumor regression in the treated animals under the experimental conditions.

The bacterium appeared to combine direct tumor-cell killing with activation of the immune system.

The treated mice also demonstrated evidence of protection against subsequent tumor rechallenge.

Those are extraordinary findings for a preclinical study.

But they remain preclinical findings.

The real test will be whether the biology survives the journey from mouse to human.

If it does, Ewingella americana could become part of a much larger shift toward living cancer therapeutics, where microorganisms are not merely passive delivery systems but active participants in the fight against disease.

The frog did not evolve a cure for cancer.

It may simply have been carrying an organism that researchers had not yet learned how to use.

Research Paper

Iwata, S., Yamasita, N., Asukabe, K., Sakari, M., & Miyako, E. (2025). Discovery and characterization of antitumor gut microbiota from amphibians and reptiles: Ewingella americana as a novel therapeutic agent with dual cytotoxic and immunomodulatory properties. Gut Microbes, 17(1), 2599562.

DOI: 10.1080/19490976.2025.2599562.

Read the full paper on PubMed Central